For the quarter ending 2026-03-31, KALV made $40,863K in revenue. -$23,474K in net income. Net profit margin of -57.45%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-07-31 |
|---|---|---|---|---|
| Total revenues | 40,863 | 26,402* | 13,692 | 1,426 |
| Cost of revenue | 3,090 | 348* | 1,232 | 590 |
| Research and development | 12,420 | -7,361* | 11,993 | 15,162 |
| Selling, general and administrative | 48,795 | -12,136* | 46,517 | 44,683 |
| Total operating expenses | 64,305 | -19,150* | 59,742 | 60,435 |
| Operating gain | -23,442 | 45,552* | -46,050 | -59,009 |
| Interest income | 2,548 | 203* | 1,875 | 1,849 |
| Interest expense | 5,586 | 477* | 4,757 | 3,522 |
| Foreign currency exchange (gain) loss | -52 | -1,531* | -884 | 1,925 |
| Other income, net | 3,045 | 3,593* | 2,491 | 818 |
| Total other (expense) income | -45 | 1,788* | -1,275 | 1,070 |
| Gain before income tax expense | -23,487 | 47,339* | -47,325 | -57,939 |
| Income tax (benefit) expense | - | -7,504* | 2,157 | 2,157 |
| Net gain | -23,487 | 54,843* | -49,482 | -60,096 |
| Foreign currency translation gain (loss) | 280 | -1,464* | 911 | -604 |
| Unrealized holding loss (gain) on marketable securities | -278 | 9* | 187 | 18 |
| Reclassification adjustment for realized holding (income) gain on marketable securities included in net gain | -11 | -810* | 771 | 587 |
| Total other comprehensive income (loss) | 13 | -646* | 327 | -1,173 |
| Comprehensive gain | -23,474 | 54,197 | -49,155 | -61,269 |
| Basic EPS | -0.43 | 0.999 | -0.92 | -1.12 |
| Diluted EPS | -0.43 | 0.999 | -0.92 | -1.12 |
| Basic Average Shares | 54,583,424 | 54,229,212 | 53,883,681 | 53,497,128 |
| Diluted Average Shares | 54,583,424 | 54,229,212 | 53,883,681 | 53,497,128 |
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)